Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00877383 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease
A Phase 3 study of Chronic Obstructive Pulmonary Disease (COPD), sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,142
- Enrollment target
- 20
- Study locations
NCT00877383 is a Phase 3 study of Chronic Obstructive Pulmonary Disease (COPD) that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 1,142 participants, above the 619-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target (84% higher). The trial reports 20 study locations across 5 states.
The verdict
NCT00877383, a Phase 3 study of Chronic Obstructive Pulmonary Disease (COPD), has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,142 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study assessed the efficacy and safety of indacaterol (150 µg once daily \[od\]) when combined with tiotropium (18 µg od) versus tiotropium (18 µg od) treatment alone in patients with chronic obstructive pulmonary disease (COPD).
Conditions Studied
Interventions
- DRUG Placebo to indacaterol
- DRUG Indacaterol 150 μg
- DRUG Tiotropium 18 μg
Study Locations (20)
California
- Novartis Investigator Site - Buena Park
- Novartis Investigator Site - Fullerton
- Novartis Investigator Site - Mission Viejo
- Novartis Investigator Site - San Ramon
- Novartis Investigator Site - Santa Barbara
- Novartis Investigator Site - Sepulveda
- Novartis Investigator Site - Spring Valley
- Novartis Investigator Site - Torrance
- Novartis Investigator Site - Torrance
- Novartis Investigator Site - Vista
Alabama
- Novartis Investigator Site - Anniston
- Novartis Investigator Site - Birmingham
- Novartis Investigator Site - Jasper
- Novartis Investigator Site - Mobile
Arizona
- Novartis Investigator Site - Glendale
- Novartis Investigator Site - Phoenix
- Novartis Investigator Site - Phoenix
- Novartis Investigator Site - Scottsdale
Arkansas
- Novartis Investigator Site - Little Rock
Colorado
- Novartis Investigator Site - Boulder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,142 participants |
| Start Date | 2009-04 |
| Est. Completion | 2010-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00877383
The ClinicalTrials.gov registry entry for NCT00877383 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,142 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 619-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target (84% higher). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Obstructive Pulmonary Disease (COPD) appearing as the primary indexed condition, and to 3 interventions - of which Placebo to indacaterol is the first listed.
NCT00877383 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT00877383 about?
NCT00877383 is a clinical study titled "Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease". This study assessed the efficacy and safety of indacaterol (150 µg once daily \[od\]) when combined with tiotropium (18 µg od) versus tiotropium (18 µg od) treatment alone in patients with chronic obstructive pulmonary disease (COPD).
What is the current status of trial NCT00877383?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,142 participants. The study started on 2009-04. Estimated completion is 2010-02.
What conditions does trial NCT00877383 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease (COPD).
What interventions are being tested in trial NCT00877383?
The interventions under investigation include: Placebo to indacaterol (DRUG), Indacaterol 150 μg (DRUG), Tiotropium 18 μg (DRUG).
Who is sponsoring clinical trial NCT00877383?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00877383 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease (COPD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Multi-Center Clean Air Randomized Controlled Trial in COPD
RECRUITING · Phase 3
-
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
RECRUITING · Phase 3
-
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.
ACTIVE NOT RECRUITING · Phase 3
-
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.